Literature DB >> 22108340

Faecal calprotectin in HIV-infected, HAART-naïve Ugandan children.

E Hestvik1, E Olafsdottir, T Tylleskar, L Aksnes, D Kaddu-Mulindwa, G Ndeezi, J K Tumwine, L Grahnquist.   

Abstract

OBJECTIVES: Calprotectin is a calcium- and zinc-binding protein and a marker in faeces of gastrointestinal inflammation. Reference values have been established in children older than 4 years. The aim of the present study was to determine the concentration of faecal calprotectin (FC) in human immunodeficiency virus (HIV)-infected, highly active antiretroviral therapy-naïve Ugandan children and compare it with the reference value.
METHODS: We tested 193 HIV-infected children ages 0 to 12 years in a hospital-based survey for FC. A standardised interview with sociodemographic information and medical history was used to assess risk factors. A cluster of differentiation 4 (CD4) cell percentage was prevalent in all of the children.
RESULTS: The median FC concentrations decreased with increasing age, as in healthy children. The median concentration was 208 mg/kg in infants 0 to 1 year, 171 mg/kg among toddlers 1 to 4 years, and 62 mg/kg for children 4 to 12 years. Children with advanced disease and a low CD4 cell percentage had significantly higher FC concentrations than those with a high CD4 cell percentage. Children older than 4 years with diarrhoea had significantly higher FC concentrations compared with those without diarrhoea.
CONCLUSIONS: HIV-infected children older than 4 years had a median FC concentration above the reference value, and gut inflammation in the children with elevated values is likely. Children with more advanced disease had increased FC concentrations regardless of age.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22108340     DOI: 10.1097/MPG.0b013e318241a683

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

1.  Association of intestinal and systemic inflammatory biomarkers with immune reconstitution in HIV+ patients on ART.

Authors:  Mariana Del Rocio Ruiz-Briseño; Judith Carolina De Arcos-Jiménez; Sarah Ratkovich-González; Karina Sánchez-Reyes; Luz A González-Hernández; Jaime F Andrade-Villanueva; Monserrat Alvarez-Zavala
Journal:  J Inflamm (Lond)       Date:  2020-10-15       Impact factor: 4.981

Review 2.  Calprotectin: Clinical Applications in Pediatrics.

Authors:  Oscar R Herrera; Michael L Christensen; Richard A Helms
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jul-Aug

Review 3.  The role of calprotectin in pediatric disease.

Authors:  George Vaos; Ioannis D Kostakis; Nick Zavras; Athanasios Chatzemichael
Journal:  Biomed Res Int       Date:  2013-09-23       Impact factor: 3.411

4.  Fecal Calprotectin Is Elevated in HIV and Related to Systemic Inflammation.

Authors:  Allison Ross Eckard; Heather Y Hughes; Nancy L Hagood; Mary Ann O'Riordan; Danielle Labbato; Julia C Kosco; Sarah E Scott; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2021-02-01       Impact factor: 3.771

5.  Gut and mesenteric lymph node involvement in pediatric patients infected with human immunodeficiency virus.

Authors:  Cecilia Mantegazza; Giovanni Maconi; Vania Giacomet; Federica Furfaro; Chiara Mameli; Cristina Bezzio; Michela Monteleone; Giulia Ramponi; Gian Vincenzo Zuccotti
Journal:  HIV AIDS (Auckl)       Date:  2014-05-08

6.  Plasma calprotectin as a biomarker of mortality at antiretroviral treatment initiation in advanced HIV - pilot study.

Authors:  Faith W Kamau; Agnes Gwela; Andrew K Nyerere; Victor Riitho; James M Njunge; Moses M Ngari; Andrew J Prendergast; James A Berkley
Journal:  Wellcome Open Res       Date:  2020-11-27

7.  Fecal calprotectin levels are higher in rural than in urban Chinese infants and negatively associated with growth.

Authors:  Jin-Rong Liu; Xiao-Yang Sheng; Yan-Qi Hu; Xiao-Gang Yu; Jamie E Westcott; Leland V Miller; Nancy F Krebs; K Michael Hambidge
Journal:  BMC Pediatr       Date:  2012-08-23       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.